88 related articles for article (PubMed ID: 17122632)
1. An inverse relation between COX-2 and E-cadherin expression correlates with aggressive histologic features in prostate cancer.
Rao DS; Gui D; Koski ME; Popoviciu LM; Wang H; Reiter RE; Said JW
Appl Immunohistochem Mol Morphol; 2006 Dec; 14(4):375-83. PubMed ID: 17122632
[TBL] [Abstract][Full Text] [Related]
2. Expression of P-cadherin identifies prostate-specific-antigen-negative cells in epithelial tissues of male sexual accessory organs and in prostatic carcinomas. Implications for prostate cancer biology.
Soler AP; Harner GD; Knudsen KA; McBrearty FX; Grujic E; Salazar H; Han AC; Keshgegian AA
Am J Pathol; 1997 Aug; 151(2):471-8. PubMed ID: 9250159
[TBL] [Abstract][Full Text] [Related]
3. E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
Rubin MA; Mucci NR; Figurski J; Fecko A; Pienta KJ; Day ML
Hum Pathol; 2001 Jul; 32(7):690-7. PubMed ID: 11486167
[TBL] [Abstract][Full Text] [Related]
4. [Correlation and significance of E-cadherin and N-cadherin expression in prostate cancer].
Huang X; Zhou LQ; Ai JK; Lu YQ; Bai Y; Zeng L; Zhang ZW; Guo YL
Ai Zheng; 2002 Nov; 21(11):1208-11. PubMed ID: 12526217
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence.
Cohen BL; Gomez P; Omori Y; Duncan RC; Civantos F; Soloway MS; Lokeshwar VB; Lokeshwar BL
Int J Cancer; 2006 Sep; 119(5):1082-7. PubMed ID: 16557596
[TBL] [Abstract][Full Text] [Related]
6. Expression of α5-integrin, α7-integrin, Ε-cadherin, and N-cadherin in localized prostate cancer.
Drivalos A; Chrisofos M; Efstathiou E; Kapranou A; Kollaitis G; Koutlis G; Antoniou N; Karanastasis D; Dimopoulos MA; Bamias A
Urol Oncol; 2016 Apr; 34(4):165.e11-8. PubMed ID: 26652134
[TBL] [Abstract][Full Text] [Related]
7. Tissue metabolite profiling identifies differentiating and prognostic biomarkers for prostate carcinoma.
Jung K; Reszka R; Kamlage B; Bethan B; Stephan C; Lein M; Kristiansen G
Int J Cancer; 2013 Dec; 133(12):2914-24. PubMed ID: 23737455
[TBL] [Abstract][Full Text] [Related]
8. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer.
Umbas R; Schalken JA; Aalders TW; Carter BS; Karthaus HF; Schaafsma HE; Debruyne FM; Isaacs WB
Cancer Res; 1992 Sep; 52(18):5104-9. PubMed ID: 1516067
[TBL] [Abstract][Full Text] [Related]
9. E-cadherin: a marker for differentiation and invasiveness in prostatic carcinoma.
Otto T; Rembrink K; Goepel M; Meyer-Schwickerath M; Rübben H
Urol Res; 1993; 21(5):359-62. PubMed ID: 7506464
[TBL] [Abstract][Full Text] [Related]
10. Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer.
Zellweger T; Günther S; Zlobec I; Savic S; Sauter G; Moch H; Mattarelli G; Eichenberger T; Curschellas E; Rüfenacht H; Bachmann A; Gasser TC; Mihatsch MJ; Bubendorf L
Int J Cancer; 2009 May; 124(9):2116-23. PubMed ID: 19117060
[TBL] [Abstract][Full Text] [Related]
11. E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome.
Ross JS; Figge HL; Bui HX; del Rosario AD; Fisher HA; Nazeer T; Jennings TA; Ingle R; Kim DN
Mod Pathol; 1994 Oct; 7(8):835-41. PubMed ID: 7530850
[TBL] [Abstract][Full Text] [Related]
12. E-cadherin protein expression predicts prostate cancer salvage radiotherapy outcomes.
Ray ME; Mehra R; Sandler HM; Daignault S; Shah RB
J Urol; 2006 Oct; 176(4 Pt 1):1409-14; discussion 1414. PubMed ID: 16952645
[TBL] [Abstract][Full Text] [Related]
13. Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease.
Di Lorenzo G; De Placido S; Autorino R; De Laurentiis M; Mignogna C; D'Armiento M; Tortora G; De Rosa G; D'Armiento M; De Sio M; Bianco AR; D'Armiento FP
Prostate Cancer Prostatic Dis; 2005; 8(1):54-9. PubMed ID: 15655565
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of E-cadherin and ezrin immunohistochemical expression in prostate cancer.
Musiał J; Sporny S; Nowicki A
Pol J Pathol; 2007; 58(4):235-43. PubMed ID: 18459457
[TBL] [Abstract][Full Text] [Related]
15. N-myc downstream regulated gene-1/Cap43 may play an important role in malignant progression of prostate cancer, in its close association with E-cadherin.
Song Y; Oda Y; Hori M; Kuroiwa K; Ono M; Hosoi F; Basaki Y; Tokunaga S; Kuwano M; Naito S; Tsuneyoshi M
Hum Pathol; 2010 Feb; 41(2):214-22. PubMed ID: 19800102
[TBL] [Abstract][Full Text] [Related]
16. Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer.
Horvath LG; Henshall SM; Lee CS; Kench JG; Golovsky D; Brenner PC; O'Neill GF; Kooner R; Stricker PD; Grygiel JJ; Sutherland RL
Int J Cancer; 2005 Jan; 113(3):415-22. PubMed ID: 15455387
[TBL] [Abstract][Full Text] [Related]
17. The Gleason score of tumor at the margin in radical prostatectomy is predictive of biochemical recurrence.
Cao D; Kibel AS; Gao F; Tao Y; Humphrey PA
Am J Surg Pathol; 2010 Jul; 34(7):994-1001. PubMed ID: 20505501
[TBL] [Abstract][Full Text] [Related]
18. Expression of E-cadherin in primary prostate cancer: correlation with clinical features.
Kuczyk M; Serth J; Machtens S; Bokemeyer C; Bathke W; Stief C; Jonas U
Br J Urol; 1998 Mar; 81(3):406-12. PubMed ID: 9523661
[TBL] [Abstract][Full Text] [Related]
19. Relationship between LSD1 expression and E-cadherin expression in prostate cancer.
Wang M; Liu X; Jiang G; Chen H; Guo J; Weng X
Int Urol Nephrol; 2015 Mar; 47(3):485-90. PubMed ID: 25627913
[TBL] [Abstract][Full Text] [Related]
20. Aberrant expression of E-cadherin and beta-catenin in human prostate cancer.
Jaggi M; Johansson SL; Baker JJ; Smith LM; Galich A; Balaji KC
Urol Oncol; 2005; 23(6):402-6. PubMed ID: 16301117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
